As previously reported, Needham analyst David Saxon upgraded Globus Medical (GMED) to Buy from Hold with a $112 price target following the company’s Q4 revenue pre-announcement. The firm estimates Nevro’s EBITDA margin reached 20% and its math suggests continued expansion in 2026 could help drive high-single to low-double digit percentage upside potential to Globus’ 2026 EPS guidance. The firm also expects organic growth to improve and sees upside potential to revenue guidance, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical initiated with a Buy at TD Cowen
- TD Cowen Initiates Globus Medical with Buy Rating on Durable U.S. Spine Growth and Upside from Margin Expansion
- Globus Medical price target raised to $112 from $105 at Canaccord
- Video: Defense stocks boosted by Trump budget request
- Globus Medical price target raised to $115 from $90 at Piper Sandler